Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Licenses Patent for RNA QC Technology from Rutgers, RUCDR

NEW YORK (GenomeWeb News) – WaferGen Bio-systems said today it has acquired an exclusive license to a patent covering a novel RNA Quality Control technology.

The patent was acquired from Rutgers University and was developed at RUCDR Infinite Biologics, a cell and DNA repository located on the campus of the university. WaferGen plans to develop and commercialize products based on the patent using its high-throughput qPCR SmartChip System for profiling and validating molecular biomarkers, it said. The products would address unmet needs in the field of research and clinical RNA analysis, Fremont, Calif.-based WaferGen added.

"Assessing the quality and integrity of RNA samples is of paramount importance prior to conducting experiments," Jay Tischfield, founder and CEO of RUCDR, said in a statement. "Current QC methods use indirect measurements and lack the robustness and veracity needed to make conclusive assessments of the samples' quality.

"Our approach incorporates multiple tissue dependent cDNA measurements and provides a much more stringent measure of sample quality as it pertains to downstream analyses. WaferGen's high-throughput qPCR platform allows us to implement our multi-analyte solution in a rapid and cost-effective manner," he said.

Financial and other terms of the deal were not disclosed.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.